Page 76 - Read Online

Casolino et al. Hepatoma Res 2021;7:76 https://dx.doi.org/10.20517/2394-5079.2021.79 Page 19 of 23

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D; ESMO Guidelines Committee. Biliary cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v28-37. DOI PubMed
2. Valle JW, Kelley RK, Nervi B, Oh D, Zhu AX. Biliary tract cancer. Lancet 2021;397:428-44. DOI PubMed
3. Spolverato G, Kim Y, Ejaz A, et al. Conditional probability of long-term survival after liver resection for intrahepatic
cholangiocarcinoma: a multi-institutional analysis of 535 patients. JAMA Surg 2015;150:538-45. DOI PubMed
4. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery
2013;153:811-8. DOI PubMed PMC
5. Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic
cholangiocarcinoma. Ann Surg Oncol 2015;22:4020-8. DOI PubMed
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. DOI PubMed
7. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI PubMed
8. Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary
tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021;22:690-701. DOI PubMed PMC
9. Javle MM, Borbath I, Clarke SJ, et al. Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3
study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. J Clin Oncol
2019;37:TPS4155. DOI
10. Abou-alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy):
a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796-807. DOI PubMed PMC
11. Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J
Hepatol 2020;73:170-85. DOI PubMed
12. Marin JJG, Prete MG, Lamarca A, et al; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European
Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary
cancer. Br J Cancer 2020;123:1047-59. DOI PubMed PMC
13. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a
phase 2 clinical trial. JAMA Oncol 2019;5:824-30. DOI PubMed PMC
14. Yoo C, Kim K, Kim I, et al. Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients
with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative
randomized phase 2b study (NIFTY). J Clin Oncol 2021;39:4006-4006. DOI
15. Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or
metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010;11:1142-8. DOI PubMed
16. Chen JS, Hsu C, Chiang NJ, et al; Taiwan Cooperative Oncology Group. A KRAS mutation status-stratified randomized phase II trial
of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol 2015;26:943-9.
DOI PubMed
17. Peck J, Wei L, Zalupski M, O'Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may not be an interesting target in biliary
cancers: results of an early phase II study with lapatinib. Oncology 2012;82:175-9. DOI PubMed
18. Ahn DH, Li J, Wei L, et al. Results of an abbreviated phase-II study with the akt inhibitor MK-2206 in patients with advanced biliary
cancer. Sci Rep 2015;5:12122. DOI PubMed PMC
19. Bridgewater J, Lopes A, Beare S, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced
or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer 2016;16:153. DOI PubMed PMC
20. Goyal L, Yurgelun MB, Abrams TA, et al. A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma. J
Clin Oncol 2015;33:800-800. DOI
21. Lee J, Park SH, Chang H, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre,
open-label, randomised, phase 3 study. Lancet Oncol 2012;13:181-8. DOI PubMed
22. Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer
(BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014;15:819-28. DOI PubMed PMC
23. Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced
biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol
2010;11:48-54. DOI PubMed
24. Demols A, Borbath I, Van den Eynde M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally
advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol 2020;31:1169-77. DOI
PubMed